Clinical trials: Single Women
Healthy Volunteer
Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval
The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.
- Trial name
- NCT04898907
- Testing
- ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Moxifloxacin Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Angion Biomedica Corp
Neoplasm Malignant, Epithelial Ovarian Cancer
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to…
- Conditions
- Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Trial name
- NCT04726332
- Testing
- XL102, Fulvestrant, Abiraterone
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Exelixis
Overactive Bladder(OAB)
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
A randomized, open-label, single-dose, replicate crossover study to compare the pharmacokinetics and safety in healthy adult volunteers following oral administration of JLP-2002
- Trial name
- NCT04914221
- Testing
- JLP-2002, Comparator
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Melanoma, NSCLC
A Study of BCD-135 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, NSCLC, Renal Cell Carcinoma, Bladder Cancer
- Trial name
- NCT03464032
- Testing
- BCD-135
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Biocad
Contraception, Postcoital
Effect of Piroxicam on Ovulation
In this study the effect of piroxicam on the ovulation will be evaluated. Therefore piroxicam will be administered as a single-dose after onset of LH surge (luteinizing hormone, hormone which triggers ovulation).
- Trial name
- NCT01320709
- Testing
- Piroxicam ( BAYl1902)
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Colitis, Ulcerative
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the…
- Conditions
- Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
- Trial name
- NCT07654751
- Testing
- Breast Milk Sample Collection, Guselkumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalative administration of increasing doses in healthy male and female volunteers
- Trial name
- NCT02194777
- Testing
- BIBN 4096 BS - in single rising doses
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fasting conditions.
- Trial name
- NCT00882700
- Testing
- Cefdinir 300 mg Capsule (Sandoz, Austria), Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Chronic Kidney Disease
Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis
The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week…
- Trial name
- NCT00436995
- Testing
- Darbepoetin Alfa
- Volunteers
- 114 people
- Sponsor
- Amgen
Tuberculosis
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on…
- Trial name
- NCT06354257
- Testing
- Microgynon, GSK3036656
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atypical Hemolytic Uremic Syndrome (aHUS)
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
- Trial name
- NCT02949128
- Testing
- Ravulizumab
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy
Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions
The objective of the current study is to investigate the relative bioavailability of two different doses of BI 201335, administered as soft gelatine capsule in comparison to the equivalent doses of three different oral solution…
- Trial name
- NCT01764945
- Testing
- BI 201335 (Reference), BI 201335 (Test)
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Vulvovaginal Candidiasis
Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis
This single-center, randomized, single-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of oral Lactobacillus crispatus Lc-G22 as adjunctive therapy to clotrimazole for preventing recurrence of…
- Trial name
- NCT07727967
- Testing
- Lactobacillus crispatus Lc-G22
- Where
- China
- Volunteers
- 100 people
- Sponsor
- BioGrowing Co., Ltd
Ovarian Cancer
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with…
- Trial name
- NCT02580058
- Testing
- avelumab, PLD
- Where
- 295 sites in United States, Australia and 23 more
- Volunteers
- 566 people
- Sponsor
- Pfizer
Healthy
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers
The primary purpose of this study is to assess the safety and tolerability of AZD1446 following single dose administration.
- Trial name
- SAD (NCT00803855)
- Testing
- AZD1446
- Where
- Sweden
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
The primary objective of this study is to compare the change in estimated glomerular filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment.
- Trial name
- NCT01843790
- Testing
- GCS-100
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- La Jolla Pharmaceutical Company
Healthy
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK…
- Trial name
- NCT02300350
- Testing
- Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.